Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19
Ali S. Omrani, Sameer A. Pathan, Sarah A. Thomas, et al.
EClinicalMedicine (2020) Vol. 29-30, pp. 100645-100645
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Drug treatments for covid-19: living systematic review and network meta-analysis
Reed Siemieniuk, Jessica Bartoszko, Dena Zeraatkar, et al.
BMJ (2020), pp. m2980-m2980
Open Access | Times Cited: 796
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Eugenia Abaleke, Mustafa Abbas, Sadia Abbasi, et al.
The Lancet (2021) Vol. 397, Iss. 10274, pp. 605-612
Open Access | Times Cited: 531
ESCMID COVID-19 living guidelines: drug treatment and clinical management
Michele Bartoletti, Özlem Kurt Azap, Aleksandra Barać, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 222-238
Open Access | Times Cited: 139
Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials
Charan Thej Reddy Vegivinti, Kirk W. Evanson, Hannah Lyons, et al.
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 93
Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial
Timothy S.C. Hinks, Lucy Cureton, Ruth Knight, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 10, pp. 1130-1140
Open Access | Times Cited: 79
Antibiotics for the treatment of COVID-19
Maria Popp, Miriam Stegemann, Manuel Riemer, et al.
Cochrane library (2021) Vol. 2022, Iss. 7
Open Access | Times Cited: 77
Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial
Christine Johnston, Elizabeth R. Brown, Jenell Stewart, et al.
EClinicalMedicine (2021) Vol. 33, pp. 100773-100773
Open Access | Times Cited: 62
Efficacy and safety of azithromycin in Covid‐19 patients: A systematic review and meta‐analysis of randomized clinical trials
Ahmed Kamel, Mona S. Abdel Monem, Nour A. Sharaf, et al.
Reviews in Medical Virology (2021) Vol. 32, Iss. 1
Open Access | Times Cited: 49
The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters
Iart Luca Shytaj, Mohamed Fares, Lara Gallucci, et al.
mBio (2022) Vol. 13, Iss. 2
Open Access | Times Cited: 35
Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies
Elisa Souza Vaz, Sandra V. Vassiliades, Jeanine Giarolla, et al.
European Journal of Clinical Pharmacology (2023) Vol. 79, Iss. 6, pp. 723-751
Open Access | Times Cited: 16
The equivocal healthcare market in Bangladesh during the COVID‐19 pandemic: Policy, politics and life
Nur Newaz Khan
The Australian Journal of Anthropology (2025)
Closed Access
Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider
Alessia Alunno, Aurélie Najm, Xavier Mariette, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 6, pp. 803-815
Open Access | Times Cited: 38
Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
Chenyang Zhang, Huaqing Jin, Yi Feng Wen, et al.
Frontiers in Public Health (2021) Vol. 9
Open Access | Times Cited: 38
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19
Caleb P Skipper, David R. Boulware
Annals of Internal Medicine (2021) Vol. 174, Iss. 3, pp. 434-435
Closed Access | Times Cited: 36
Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells
Judith Grau-Expósito, David Perea, Marina Suppi, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 1, pp. e1010171-e1010171
Open Access | Times Cited: 24
Effect of COVID‐19 medications on corrected QT interval and induction of torsade de pointes: Results of a multicenter national survey
Majid Haghjoo, Reza Golipra, Jalal Kheirkhah, et al.
International Journal of Clinical Practice (2021) Vol. 75, Iss. 7
Open Access | Times Cited: 31
Review of epidemic, containment strategies, clinical management, and economic evaluation of COVID-19 pandemic
Chi‐Ling Chen, Chao-Chih Lai, Dih-Ling Luh, et al.
Journal of the Formosan Medical Association (2021) Vol. 120, pp. S6-S18
Open Access | Times Cited: 23
Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 1)
Amir Qaseem, Jennifer Yost, Matthew C. Miller, et al.
Annals of Internal Medicine (2022) Vol. 176, Iss. 1, pp. 115-124
Open Access | Times Cited: 16
Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials
Qinglin Cheng, Chen Jun-fang, Qingjun Jia, et al.
Aging (2021) Vol. 13, Iss. 18, pp. 21866-21902
Open Access | Times Cited: 22
Newly Emerged Antiviral Strategies for SARS-CoV-2: From Deciphering Viral Protein Structural Function to the Development of Vaccines, Antibodies, and Small Molecules
Chunye Zhang, Ming Yang
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 11, pp. 6083-6083
Open Access | Times Cited: 15
Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Review for the American College of Physicians
Isolde Sommer, Andreea Dobrescu, Dominic Ledinger, et al.
Annals of Internal Medicine (2022) Vol. 176, Iss. 1, pp. 92-104
Open Access | Times Cited: 15
Care for adults with COVID ‐19: living guidelines from the National COVID ‐19 Clinical Evidence Taskforce
Heath White, Steve McDonald, Bridget E. Barber, et al.
The Medical Journal of Australia (2022) Vol. 217, Iss. 7, pp. 368-378
Open Access | Times Cited: 14
Accelerated Repurposing and Drug Development of Pulmonary Hypertension Therapies for COVID-19 Treatment Using an AI-Integrated Biosimulation Platform
Kaushik Chakravarty, Victor Antontsev, Maksim Khotimchenko, et al.
Molecules (2021) Vol. 26, Iss. 7, pp. 1912-1912
Open Access | Times Cited: 19
Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API)
Alexandre Naime Barbosa, Alberto Chebabo, Carlos Ernesto Ferreira Starling, et al.
Annals of Clinical Microbiology and Antimicrobials (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Efficacy and Safety of Azithromycin for the Treatment of COVID-19: A Systematic Review and Meta-analysis
Ghea Mangkuliguna, Glenardi Glenardi, Natalia Natalia, et al.
Tuberculosis & respiratory diseases (2021) Vol. 84, Iss. 4, pp. 299-316
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top